Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18614534 | 1.00 | DGAT1 (0.54) | DGAT1NAPRTL3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL7710462 | 0.80 | SMN1; SMN2 (0.40) | L3MBTL1HTTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL7710467 | 0.80 | SMN1; SMN2 (0.40) | L3MBTL1HTTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL425120 | 0.78 | HTT (0.61) | L3MBTL1HTTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL446955 | 0.78 | HTT (0.61) | L3MBTL1HTTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL8344692 | 0.77 | CYP11B1 (0.44) | L3MBTL1HTTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL22291361 | 0.76 | L3MBTL1 (0.40) | L3MBTL1HTTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL22291363 | 0.76 | L3MBTL1 (0.40) | L3MBTL1HTTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL31473960 | 0.76 | L3MBTL1 (0.40) | L3MBTL1HTTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL29370580 | 0.76 | L3MBTL1 (0.40) | L3MBTL1HTTSMN1; SMN2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112409378-A | Tricyclic PI3K inhibitor compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-108349996-B | Tricyclic PI3K inhibitor compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-01-08 | — | — | CN | disclosed |
| EP-3347361-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2020-08-05 | — | — | EP | disclosed |
| US-10435414-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180327420-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-11-15 | — | — | US | disclosed |
| US-10065970-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| EP-3347361-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | H. Hoffnabb-La Roche Ag (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| WO-2017042182-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435414-B2 | Tricyclic PI3K inhibitor compounds and methods of use | PIK3CA, PIK3CD, PIK3CB | DGAT1 1629/4885NAPRT 1623/4885L3MBTL1 4168/4885 |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | DGAT1 1629/4885NAPRT 1623/4885L3MBTL1 4168/4885 |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | DGAT1 1629/4885NAPRT 1623/4885L3MBTL1 4168/4885 |
| US-20180327420-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | DGAT1 1629/4885NAPRT 1623/4885L3MBTL1 4168/4885 |
| US-10065970-B2 | Tricyclic PI3K inhibitor compounds and methods of use | PIK3CA, PIK3CD, PIK3CB | DGAT1 1629/4885NAPRT 1623/4885L3MBTL1 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.